Heart Corner: Innovations in Cardiovascular Science

This JACC State-of-the-Art Review article provides a comprehensive overview of transcatheter tricuspid valve replacement (TTVR) for treating severe tricuspid regurgitation. The paper examines patient selection criteria, procedural techniques, and post-procedure care, including management of complications like conduction disturbances and bleeding. It details various TTVR systems and their characteristics,  presents clinical evidence from studies and registries, and discusses diagnostic imaging and hemodynamic assessment. Finally, the article outlines future research directions in TTVR and related interventions.

This research review article from Circulation: Cardiovascular Interventions focuses on managing large-bore vascular access (≥12 French) during transfemoral procedures, such as heart interventions and electrophysiology.  The authors explore optimal puncture techniques, including ultrasound guidance, and various hemostasis strategies, comparing suture-based and plug-based vascular closure devices (VCDs).  Management of VCD failures and venous access complications are also discussed, outlining bail-out strategies and alternative closure methods. The article aims to minimize vascular complications and improve patient outcomes by optimizing large-bore access management from puncture to sheath removal.

This JACC manuscript details a first-in-human study evaluating the Magenta Elevate, a novel high-output mechanical circulatory support (MCS) catheter. The study assessed its safety and efficacy during high-risk percutaneous coronary intervention (PCI), particularly in left main coronary artery interventions. Results showed the device to be safe, with no major adverse events, and effective in maintaining hemodynamic stability even during prolonged balloon occlusions. The high output of the pump resulted in left ventricular unloading and ventriculo-arterial uncoupling in many patients. Further research is needed to confirm these initial findings.

1. Généreux, P, Banovic, M, Kang, D. et al. Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. JACC. null2024, 0 (0) . https://doi.org/10.1016/j.jacc.2024.11.006

2. Warraich, H, Patrick-Lake, B, Saha, A. et al. Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration. JACC. null2024, 0 (0) .

https://doi.org/10.1016/j.jacc.2024.10.075

3. Jain, S, Sarraju, A, Shah, N. et al. The Coming AI Revolution in Clinical Trials. JACC. null2024, 0 (0) .https://doi.org/10.1016/j.jacc.2024.10.093

This JACC State-of-the-Art Review article provides a comprehensive overview of transcatheter tricuspid valve replacement (TTVR) for treating severe tricuspid regurgitation. The article details current TTVR systems, their mechanisms, and clinical outcomes from various studies, including a randomized controlled trial. It also explores diagnostic work-up, patient selection criteria, procedural considerations (such as managing complications like bleeding and conduction disturbances), and post-procedure care, including anticoagulation strategies. The authors offer expert recommendations based on their experience, highlighting both the potential benefits and challenges associated with TTVR. Finally, the review discusses future research directions and ongoing clinical trials aimed at expanding the understanding and application of this evolving therapy.

The first trial examines the effects of tirzepatide on patients with heart failure with preserved ejection fraction and obesity. The study found that tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo, improving health status and exercise tolerance. The second trial evaluates the use of colchicine in patients who have experienced an acute myocardial infarction, finding no significant reduction in the composite outcome of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization despite a longer treatment duration. The third trial reports on the use of spironolactone in patients who have experienced an acute myocardial infarction, with the results demonstrating no significant decrease in the risk of death from cardiovascular causes or new or worsening heart failure or the composite outcome of death from cardiovascular causes, myocardial infarction, stroke, or new or worsening heart failure. The fourth trials investigates the efficacy and safety of nex-z, a CRISPR-Cas9 gene editing therapy, for patients with transthyretin amyloidosis with cardiomyopathy. The study showed that a single dose of nex-z led to rapid and durable reductions in serum transthyretin levels with a favorable safety profile. The final trial explores the use of left atrial appendage closure as an alternative to oral anticoagulation for patients with atrial fibrillation who have undergone catheter ablation. The results suggest that left atrial appendage closure leads to a lower risk of non–procedure-related major or clinically relevant non major bleeding while being noninferior to oral anticoagulation in terms of death from any cause, stroke, or systemic embolism.

This medical paper examines the challenges older women face when undergoing percutaneous coronary intervention (PCI) for coronary artery disease. The authors highlight that older women are less likely to receive evidence-based treatment despite experiencing a higher risk of adverse events due to their unique physiological and anatomical differences. The paper discusses the limitations of current risk stratification tools in accurately assessing older women’s risk, and emphasizes the need for tailored procedural techniques and patient-centered care approaches. Furthermore, it calls attention to the limited research available on older women and the need for increased representation in clinical trials.

Summary 

This study examines the effects of different antithrombotic treatments in patients with atrial fibrillation who have had an acute coronary syndrome or undergone percutaneous coronary intervention. The researchers specifically investigated whether the timing of treatment initiation, early versus late after the index event, influences the benefits and risks of dual antiplatelet therapy plus oral anticoagulation compared to a single P2Y12 inhibitor plus oral anticoagulation. The findings suggest that a short course of dual antiplatelet therapy might be beneficial early after the event, but this requires further investigation.

This study examined the effects of an invasive strategy, including coronary angiography and subsequent revascularization, compared to a conservative approach for older adults (≥75 years) experiencing non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS). The meta-analysis of nine studies indicated that invasive strategies significantly reduced the risk of death or myocardial infarction, myocardial infarction, and subsequent revascularization without increasing the risk of major bleeding. Despite limitations, the results highlight the potential benefits of invasive strategies for older adults with NSTE‐ACS, underscoring the need for future trials to further explore the nuances of geriatric conditions and to better represent the growing older adult population.